Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02509624
Registration number
NCT02509624
Ethics application status
Date submitted
16/07/2015
Date registered
28/07/2015
Date last updated
27/01/2021
Titles & IDs
Public title
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
Query!
Scientific title
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Query!
Secondary ID [1]
0
0
2015-002444-14
Query!
Secondary ID [2]
0
0
GS-US-223-1018
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetic Kidney Disease
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Selonsertib
Experimental: Moderate hepatic impairment (Cohort 1) - Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
Experimental: Severe hepatic impairment (Cohort 2) - Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
Experimental: Mild hepatic impairment (Cohort 3) - Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
Treatment: Drugs: Selonsertib
6 mg tablets administered orally in fed state
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509
Query!
Assessment method [1]
0
0
AUCinf is defined as the concentration of drug extrapolated to infinite time.
Query!
Timepoint [1]
0
0
0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.
Query!
Primary outcome [2]
0
0
PK Parameter: AUClast of Selonsertib and Its Metabolite GS-607509
Query!
Assessment method [2]
0
0
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Query!
Timepoint [2]
0
0
0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.
Query!
Primary outcome [3]
0
0
PK Parameter: Cmax of Selonsertib and Its Metabolite GS-607509
Query!
Assessment method [3]
0
0
Cmax is defined as the maximum concentration of drug.
Query!
Timepoint [3]
0
0
0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.
Query!
Secondary outcome [1]
0
0
Percentage of Participants Experiencing Treatment-Emergent Study Drug-related Adverse Events (AEs)
Query!
Assessment method [1]
0
0
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs were defined as events that met one of the following criteria: 1) Any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; or 2) Any AEs leading to premature discontinuation of study drug.
Query!
Timepoint [1]
0
0
Day 1 plus 30 days
Query!
Secondary outcome [2]
0
0
Percentage of Participants Experiencing Any Treatment-Emergent and Grade = 3 Laboratory Abnormalities
Query!
Assessment method [2]
0
0
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study drug. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent. Severity grades were defined based on modified Common Terminology Criteria for Adverse Events (CTCAE) Laboratory Abnormality and Adverse Event Severity Grading, where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. The most severe graded abnormality from all tests was counted for each participant.
Query!
Timepoint [2]
0
0
Day 1 plus 30 days
Query!
Eligibility
Key inclusion criteria
Key
All participants:
- Body mass index (BMI) from 18 to 40 kg/m^2, inclusive at study screening
- Creatinine clearance (CrCl) = 60 mL/min (using the Cockcroft-Gault method) based on
serum creatinine and actual body weight as measured at screening
Participants with impaired hepatic function:
- Aside from hepatic insufficiency, participants must be sufficiently healthy for study
participation based upon screening evaluations.
- Must have diagnosis of chronic (> 6 months), stable hepatic impairment with no
clinically significant change in hepatic status within the 3 months (90 days) prior to
study drug administration (Day 1).
- Participants with severe hepatic impairment must have a score on the
Child-Pugh-Turcotte scale of 10-15 at screening.
- Participants with moderate hepatic impairment must have a score on the
Child-Pugh-Turcotte scale of 7-9 at screening.
- Participants with mild hepatic impairment must have a score on the Child-Pugh-Turcotte
scale of 5-6 at screening.
Healthy participants (matched control):
- Must be in good health based upon screening evaluations.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
All participants:
- Pregnant or lactating females
- Have received any investigational compound or device within 30 days prior to study
dosing
- Current alcohol or substance abuse
- A positive test result for human immunodeficiency virus (HIV-1/2) antibody
- Have poor venous access that limits phlebotomy
- Have been treated with systemic steroids, anti-HIV agents, immunosuppressant
therapies, or chemotherapeutic agents within 3 months prior to screening or expected
to receive these agents during the study (eg, corticosteroids, immunoglobulins, and
other immune- or cytokine-based therapies) that would be contraindicated for other
exclusion criteria.
- Significant serious skin disease, such as but not limited to rash, food allergy,
eczema, psoriasis, or urticaria
- Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)
- Unstable cardiac disease, including history of myocardial infarction within 1 year of
screening, recurrent episodes of ventricular tachycardia despite appropriate medical
therapy, decompensated congestive heart failure, or dilated cardiomyopathy with left
ventricular ejection fraction < 40%, or a family history of Long QT Syndrome, or
unexplained death in an otherwise healthy participants between the ages of 1 and 30
years.
- Syncope, palpitations, or unexplained dizziness
- Implanted defibrillator or pacemaker
- Severe peptic ulcer disease, severe gastroesophageal reflux disease, or other severe
gastric acid hypersecretory conditions
- Medical or surgical treatment that permanently alters gastric absorption (eg, gastric
or intestinal surgery). A history of cholecystectomy is not exclusionary.
- History of prior allogeneic bone marrow progenitor cell or solid organ
transplantation.
- Currently registered on an organ transplantation list.
- History of bleeding from esophageal varices within 90 days prior to Admission (Day
-1).
- Use of strong cytochrome P3A4 (CYP3A4) inhibitors (eg, indinavir, nelfinavir,
ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir,
suboxone, telithromycin, atazanavir) and strong CYP3A4 inducers (eg, carbamazepine,
rifampin, phenytoin and St. John's wort), within 28 days prior to study drug
administration (Day 1).
- Consumption of grapefruit juice, grapefruits, and Seville orange juice within 2 weeks
prior to study drug administration (Day 1).
- Recent significant changes in the use of nicotine or nicotine containing products
Participants with impaired hepatic function:
- Aside from hepatic insufficiency, serious or active medical or psychiatric illness
that, in the opinion of the investigator, would interfere with treatment, assessment,
or compliance with the protocol.
- Chronic hepatitis B virus (HBV) infection, defined as a positive test for hepatitis B
surface antigen (HBsAg), unless the participant has been treated with a nucleos(t)ide
analog (eg, tenofovir or entecavir) for at least 6 months and the HBV deoxyribonucleic
acid (DNA) by polymerase chain reaction (PCR) assay has been persistently undetectable
for at least 6 months.
- Positive test for drugs of abuse, including alcohol at screening or on Day
-1/check-in, with the exception of opioids and tetrahydrocannabinol (THC, marijuana)
under prescription and investigator verification for pain management. Participants who
screen positive for benzodiazepines may be allowed if prescribed under the care of a
physician and after review by investigator and Sponsor.
- Requires paracentesis > 1 time per month.
- Participants with hepatic impairment with co-morbid diseases not associated with
hepatic impairment requiring medication(s) must be taking the medication(s) without a
change in dose for > 3 months prior to screening.
- Changes in concomitant medications or dosage used to treat symptoms of hepatic
impairment or associated co-morbid conditions that could lead to clinically
significant changes in medical conditions during the course of the study that would
affect the ability to interpret potential drug-drug interactions within 28 days prior
to dosing.
Healthy participants (matched control):
- A positive test result for hepatitis C virus (HCV) antibody, hepatitis B surface
antigen (HBsAg), or hepatitis B core antibody (anti-HBc)
- Positive test for drugs of abuse, including alcohol at screening or on Day
-1/check-in.
- Have any serious or active medical or psychiatric illness (including depression)
which, in the opinion of the investigator, would interfere with treatment, assessment,
or compliance with the protocol.
- History of liver disease.
- Have taken any prescription medications or over-the-counter medications including
herbal products within 28 days of commencing study drug dosing with the exception of
vitamins, acetaminophen, ibuprofen, and hormonal contraceptive medications.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/08/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
15/12/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
52
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Colorado
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Minnesota
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Texas
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib
in participants with impaired hepatic function relative to matched, healthy controls.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02509624
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Gilead Study Director
Query!
Address
0
0
Gilead Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02509624
Download to PDF